New hope for Tough-to-Treat skin cancer: trial tests adding a third drug
Disease control
Recruiting now
This early-stage study is testing whether adding a drug called nilotinib to standard melanoma treatments (dabrafenib/trametinib or encorafenib/binimetinib) is safe and tolerable for patients. It is for adults whose advanced, BRAF-mutated melanoma has stopped responding to or prog…
Phase: PHASE1 • Sponsor: Rina Plattner • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC